Najah Abi-Gerges, Ph.D., Vice President of Research & Development at AnaBios, was recently named a new Associate Editor of the Cardiac Electrophysiology section of Frontiers in Physiology, the second most-cited journal in its field with more than 200,000 citations.

Dr. Abi-Gerges holds a MSc in Physiology and Pharmacology from the University of Poitiers (France) and a Ph.D. in Cardiac Physiology from Paris XI University (France). Prior to joining AnaBios, Dr. Abi-Gerges was involved in drug discovery programs at AstraZeneca. 

With over 17 years in the pharmaceutical industry, he is an innovative leader, having made substantial contributions to drug approvals, research across several areas of cardiac physiology and pharmacology resulting in over 40 published peer-reviewed articles, and novel paradigms to advance cardiovascular translational science.

He is also Editor for the Journal of Pharmacological and Toxicological Methods, and is also a reviewer for more than 20 peer-reviewed scientific journals and review judge panel for various science institutes and foundations. Dr. Abi-Gerges is co-chair of the ion channel group in the CiPA initiative.